Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. It also provides raw material products, including … Read more
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Net Assets
Latest net assets as of September 2025: CN¥2.26 Billion CNY
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has net assets worth CN¥2.26 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.40 Billion) and total liabilities (CN¥142.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.26 Billion |
| % of Total Assets | 94.08% |
| Annual Growth Rate | 33.37% |
| 5-Year Change | 229.77% |
| 10-Year Change | N/A |
| Growth Volatility | 71.91 |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Net Assets Trend (2017–2024)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2024)
The table below shows the annual net assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.31 Billion | -1.99% |
| 2023-12-31 | CN¥2.36 Billion | +3.52% |
| 2022-12-31 | CN¥2.28 Billion | +2.42% |
| 2021-12-31 | CN¥2.22 Billion | +217.36% |
| 2020-12-31 | CN¥700.39 Million | +43.45% |
| 2019-12-31 | CN¥488.25 Million | +22.10% |
| 2018-12-31 | CN¥399.87 Million | +29.98% |
| 2017-12-31 | CN¥307.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27423456744.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥207.55 Million | 8.99% |
| Common Stock | CN¥288.00 Million | 12.47% |
| Other Comprehensive Income | CN¥57.62 Million | 2.49% |
| Other Components | CN¥1.76 Billion | 76.05% |
| Total Equity | CN¥2.31 Billion | 100.00% |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Market Cap
The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Whirlpool of India Limited
NSE:WHIRLPOOL
|
$292.66 Million |
|
Gedik Yatirim Menkul Degerler AS
IS:GEDIK
|
$292.68 Million |
|
Baotou Dongbao Bio-Tech Co Ltd
SHE:300239
|
$292.71 Million |
|
PHARMANUTRA S.P.A.
F:761
|
$292.74 Million |
|
Danal Co. Ltd
KQ:064260
|
$292.50 Million |
|
Cinda Real Estate Co Ltd
SHG:600657
|
$292.49 Million |
|
Holtek Semiconductor Inc
TW:6202
|
$292.47 Million |
|
Jiangsu Boamax Technologies Group Co Ltd
SHE:002514
|
$292.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,356,684,841 to 2,309,688,533, a change of -46,996,308 (-2.0%).
- Net income of 91,547,379 contributed positively to equity growth.
- Dividend payments of 138,240,000 reduced retained earnings.
- Other comprehensive income increased equity by 57,621,539.
- Other factors decreased equity by 57,925,226.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥91.55 Million | +3.96% |
| Dividends Paid | CN¥138.24 Million | -5.99% |
| Other Comprehensive Income | CN¥57.62 Million | +2.49% |
| Other Changes | CN¥-57.93 Million | -2.51% |
| Total Change | CN¥- | -1.99% |
Book Value vs Market Value Analysis
This analysis compares Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.52x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.52x to 1.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.16 | CN¥12.17 | x |
| 2018-12-31 | CN¥1.35 | CN¥12.17 | x |
| 2019-12-31 | CN¥1.70 | CN¥12.17 | x |
| 2020-12-31 | CN¥2.43 | CN¥12.17 | x |
| 2021-12-31 | CN¥7.72 | CN¥12.17 | x |
| 2022-12-31 | CN¥7.90 | CN¥12.17 | x |
| 2023-12-31 | CN¥8.16 | CN¥12.17 | x |
| 2024-12-31 | CN¥8.02 | CN¥12.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hubei Biocause Heilen Pharmaceutical Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.53%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.08x
- Recent ROE (3.96%) is below the historical average (11.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 4.32% | 2.80% | 0.69x | 2.25x | CN¥-13.49 Million |
| 2018 | 16.69% | 9.23% | 0.81x | 2.24x | CN¥19.13 Million |
| 2019 | 20.54% | 15.19% | 0.89x | 1.53x | CN¥51.46 Million |
| 2020 | 24.00% | 28.35% | 0.74x | 1.15x | CN¥98.03 Million |
| 2021 | 5.47% | 22.50% | 0.23x | 1.05x | CN¥-100.63 Million |
| 2022 | 5.53% | 24.43% | 0.21x | 1.10x | CN¥-101.86 Million |
| 2023 | 7.47% | 26.56% | 0.26x | 1.08x | CN¥-59.55 Million |
| 2024 | 3.96% | 20.53% | 0.18x | 1.08x | CN¥-139.42 Million |
Industry Comparison
This section compares Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) | CN¥2.26 Billion | 4.32% | 0.06x | $292.65 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |